Please login to bookmarkClose

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au